Yahoo Poland Wyszukiwanie w Internecie

Search results

  1. 4 mar 2024 · The ultimate treatment goal in all patients with peripheral spondyloarthritis (SpA) is to optimize short- and long-term health-related quality of life, which is accomplished through use of a combination of nonpharmacologic and pharmacologic treatments to control inflammation, prevent structural damage to the joints, and preserve function and ...

  2. Adalimumab (HUMIRA ®, AbbVie, North Chicago, IL) is an anti-tumor necrosis factor (TNF) agent indicated for the treatment of 15 conditions, including adult and pediatric plaque psoriasis (Ps), hidradenitis suppurativa (HS), rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), non-radiographic axial ...

  3. Spondyloarthritis (SpA) is a group of chronic inflammatory diseases of autoimmune nature sharing common clinical and genetic features, such as involvement of the axial skeleton (sacroiliac joints and spine), a certain pattern of peripheral joint involvement (usually asymmetric monoarthritis or oligoarthritis predominantly affecting the joints ...

  4. 27 maj 2023 · For example, Humira (adalimumab) is a TNF inhibitor that is effective in people with peripheral spondyloarthritis. Peripheral spondyloarthritis is a complex condition that should be followed by a healthcare provider who specializes in the condition.

  5. 1 cze 2018 · Peripheral spondyloarthritis refers to spondyloarthritis with predominant peripheral (arthritis, enthesitis or dactylitis) involvement. Diagnosis can be challenging, particularly in the absence of SpA extra-articular manifestations such as uveitis, psoriasis or inflammatory bowel disease.

  6. Abstract. Objective: To evaluate the efficacy and safety of adalimumab in patients with active nonpsoriatic peripheral spondyloarthritis (SpA). Methods: ABILITY-2 is an ongoing phase III, multicenter study of adalimumab treatment.

  7. Several biologics and targeted synthetic (ts) DMARDs (TNFi, anti-IL17 and JAK-inhibitors) have been proven to be efficacious in peripheral involvement in PsA (arthritis and enthesitis), but studies on peripheral SpA are lacking.

  1. Ludzie szukają również